Windmill Cardiovascular Systems
- Company typePrivate
- Founded2005
- HeadquartersAustin, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Windmill Cardiovascular Systems firmographics
Firmographics- Name
- Windmill Cardiovascular Systems
- Legal name
- Windmill Cardiovascular Systems, Inc.
- Website
- https://windmillcvs.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Windmill Cardiovascular Systems industry classification
Industry- Product category
- Ventricular Assist Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Mechanical Circulatory Support (VAD, IABP, ECMO) (HLAHAFAG)
Keywords
Where Windmill Cardiovascular Systems is headquartered
LocationHeadquarters
- HQ city
- Austin
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Windmill Cardiovascular Systems business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Distribution channels1 record
Windmill Cardiovascular Systems product offering
Product offeringCore offering
Windmill Cardiovascular Systems develops the TORVAD (Toroidal Ventricular Assist Device) platform of fully implantable blood pumps for treating patients with end-stage, advanced, and pediatric heart failure. The TORVAD uses a proprietary two-piston toroidal chamber with magnetically coupled motors to produce synchronized, physiologically pulsatile flow at low rotational speeds, intended to reduce blood trauma and adverse events associated with conventional continuous-flow ventricular assist devices.
Product overview
Windmill Cardiovascular Systems offers a platform of implantable blood pump technologies centered on the TORVAD (Toroidal Ventricular Assist Device) system. The core portfolio includes the TORVAD device for full-support in end-stage heart failure and the TORVAD mini for partial adult and full pediatric support. Both products utilize a unique two-piston toroidal pumping chamber design with magnetic coupling and synchronized pulsatile flow to provide gentle blood handling compared to conventional continuous-flow devices.
Differentiator
Problem solved
Functional benefit
Products and services
- TORVAD
Quantifiable outcome
- Very low levels of fluid shear stress - orders of magnitude less than conventional impeller-based devices (verified in benchtop and animal testing)
- +1 more outcomes
Companies that use Windmill Cardiovascular Systems
Customer profileSegments1 record
Ideal customer profiles1 record
Windmill Cardiovascular Systems technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Windmill Cardiovascular Systems partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights4 records
Windmill Cardiovascular Systems competitors and assessment
Company assessmentDirect peers
- Abbott (HeartMate): Abbott's HeartMate franchise (HeartMate 3, acquired via Thoratec) is the dominant approved LVAD in the U.S. market. It is the standard of care that TORVAD would compete against directly in adult end-stage heart failure.
- Berlin Heart: Berlin Heart's EXCOR Pediatric is the only FDA-approved pediatric VAD, making it the closest competitor for TORVAD mini in pediatric heart failure support. Both companies target mechanical circulatory support in heart failure.
- Abiomed (Johnson & Johnson): Abiomed's Impella platform is a percutaneous mechanical circulatory support device widely used in cardiogenic shock and high-risk PCI. It competes in the same MCS category as TORVAD for short- and intermediate-duration ventricular support.
Broad incumbents
- Medtronic (HeartWare/HVAD): Medtronic acquired HeartWare and commercialized the HVAD before discontinuing it; it represents the historical second major LVAD incumbent and a likely strategic buyer or benchmark for next-gen pump companies.
Emerging players
- CorWave: French medtech developing a next-generation LVAD with a novel wave-membrane pump emphasizing gentle blood handling. Philosophically aligned with Windmill on reducing blood trauma versus continuous-flow devices.
- Jarvik Heart: Long-standing VAD developer (Jarvik 2000) and now developing next-generation axial-flow devices for destination therapy. An emerging competitor targeting similar advanced heart failure indications.
- BiVACOR: BiVACOR is developing a total artificial heart using a magnetically levitated rotor. It is adjacent to LVADs but represents a competing mechanical replacement for end-stage heart failure, sharing regulatory and engineering complexity.
- Evaheart: Japanese company developing the EVAHEART centrifugal continuous-flow LVAD. Emerging VAD competitor pursuing similar advanced heart failure indications in Asia and select global markets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Windmill Cardiovascular Systems social profiles
Digital presenceWindmill Cardiovascular Systems financial estimates
Financial estimateRevenue estimate
Valuation estimate
Windmill Cardiovascular Systems leadership team
Management profileNumber of profiles
Profiles7 records
Windmill Cardiovascular Systems funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Windmill Cardiovascular Systems M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Windmill Cardiovascular Systems
What does Windmill Cardiovascular Systems do?
Windmill Cardiovascular Systems develops the TORVAD (Toroidal Ventricular Assist Device) platform of fully implantable blood pumps for treating patients with end-stage, advanced, and pediatric heart failure. The TORVAD uses a proprietary two-piston toroidal chamber with magnetically coupled motors to produce synchronized, physiologically pulsatile flow at low rotational speeds, intended to reduce blood trauma and adverse events associated with conventional continuous-flow ventricular assist devices.
Is Windmill Cardiovascular Systems a public or private company?
Windmill Cardiovascular Systems is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Windmill Cardiovascular Systems founded?
Windmill Cardiovascular Systems was founded in 2005. It employs 11 to 50 people.
Where is Windmill Cardiovascular Systems based?
Windmill Cardiovascular Systems is headquartered in Austin, United States, in the North America region.
Who are Windmill Cardiovascular Systems's main competitors?
Direct peers on record are Abbott (HeartMate), Berlin Heart and Abiomed (Johnson & Johnson). Medtronic (HeartWare/HVAD) is listed as a broad incumbent. Emerging players are CorWave, Jarvik Heart, BiVACOR and Evaheart.
Does Windmill Cardiovascular Systems have an API?
No public API is recorded for Windmill Cardiovascular Systems.
What industry is Windmill Cardiovascular Systems in?
Windmill Cardiovascular Systems's product category is Ventricular Assist Devices. Its primary akta.pro industry code is HLAHAFAG, Mechanical Circulatory Support (VAD, IABP, ECMO). Its NAICS code is 334510 and its SIC code is 3842.